financetom
Business
financetom
/
Business
/
Choice Hotels International's Q2 Adjusted Earnings Rise, Revenue Declines; Lowers 2025 Adjusted EPS Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Choice Hotels International's Q2 Adjusted Earnings Rise, Revenue Declines; Lowers 2025 Adjusted EPS Guidance
Aug 6, 2025 4:56 AM

07:43 AM EDT, 08/06/2025 (MT Newswires) -- Choice Hotels International ( CHH ) reported Q2 adjusted earnings Wednesday of $1.92 per diluted share, up from $1.84 a year earlier.

Analysts surveyed by FactSet expected $1.90.

Revenue for the quarter ended June 30 was $426.4 million, up from $435 million a year earlier.

Analysts polled by FactSet expected $429.8 million.

The hospitality company said it now expects 2025 adjusted diluted EPS of $6.88 to $7.20, compared with $6.90 to $7.22 previously.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Amazon.com Launches AI Shopping Assistant Rufus in India
Amazon.com Launches AI Shopping Assistant Rufus in India
Aug 29, 2024
11:13 AM EDT, 08/27/2024 (MT Newswires) -- Amazon.com ( AMZN ) said Monday that it launched a beta version of its artificial intelligence-backed shopping assistant Rufus in India. The e-commerce giant said Rufus is trained on its product catalog and information from the internet, allowing the AI assistant to compare products, provide product recommendations, and answer customers' questions on shopping...
Legend Biotech Says China's National Medical Products Administration Approves Cell Therapy Product to Treat Multiple Myeloma
Legend Biotech Says China's National Medical Products Administration Approves Cell Therapy Product to Treat Multiple Myeloma
Aug 29, 2024
11:13 AM EDT, 08/27/2024 (MT Newswires) -- Legend Biotech ( LEGN ) said Tuesday that China's National Medical Products Administration has approved the company's cell therapy product ciltacabtagene autoleucel to treat adult patients with relapsed or refractory multiple myeloma, who received at least three previous lines of therapy. Ciltacabtagene autoleucel, or cilta-cel, is a gene-modified therapy targeting B-cell maturation antigen...
Xiao-I Awaiting China Court's Verdict in Patent Infringement Case Against Apple
Xiao-I Awaiting China Court's Verdict in Patent Infringement Case Against Apple
Aug 29, 2024
11:10 AM EDT, 08/27/2024 (MT Newswires) -- Xiao-I ( AIXI ) said Tuesday it is now awaiting the verdict in the patent infringement dispute between its variable interest entity Shanghai Xiao-i Robot Technology and Apple ( AAPL ) after the Shanghai High People's Court ended the trial on July 31. Shanghai Xiao-i ( AIXI ) filed a lawsuit in August...
Brown-Forman's 'Hangover Continues' Amid US Headwinds, RBC Says
Brown-Forman's 'Hangover Continues' Amid US Headwinds, RBC Says
Aug 29, 2024
11:13 AM EDT, 08/27/2024 (MT Newswires) -- Brown-Forman's (BF.B) hangover continues amid US headwinds and muted performance in key brands, RBC Capital Markets said Tuesday in a report. We see near term pressures continuing to weigh on numbers despite easier compares ahead, partly on slowing consumption outside the US, RBC said. Brown-Forman will announce fiscal Q1 results on Thursday. The...
Copyright 2023-2026 - www.financetom.com All Rights Reserved